1	Title Page
2	Baloxavir marboxil use for critical human infection of avian influenza A
3	H5N6 virus
4	Wenda Guan, Ph.D. ^{a,c#} , Rong Qu, M.D. ^{d#} , Lihan Shen, M.D. ^{e#} , Kailin Mai, M.Sc. ^{a#} , Weiqi Pan,
5	Ph.D. ^{a#} , Zhengshi Lin, M.D., Ph.D. ^{a#} , Liping Chen, M.Sc. ^a , Ji Dong, M.D. ^a , Jiawei Zhang,
6	B.Sc. ^a , Pei Feng, B.Sc. ^{a,f} , Yunceng Weng, Ph.D. ^a , Minfei Yu, B.Sc. ^a , Peikun Guan, B.Sc. ^a ,
7	Jinchao Zhou, B.Sc.ª, Chuanmeizi Tu, B.Sc.ª, Xiao Wu, M.Sc.ª, Yang Wang, Ph.D.ª,b,
8	Chunguang Yang, M.Sc. ^a , Yun Ling, M.D. ^d , Sheng Le, M.D. ^d , Yangqing Zhan, M.D. ^a , Yimin Li,
9	M.D.ª, Xiaoqing Liu, M.D.ª, Heyan Zou, B.Sc. ^e , Ziqi Huang, B.Sc. ^e , Hongxia Zhou, Ph.D. ^e ,
10	Qiubao Wu, B.Sc.ª, Wenjie Zhang, B.Sc.ª, Jiayang He, Ph.D.ª, Teng Xu, Ph.D. ^g , Nanshan
11	Zhong, M.D. ^{a,b*} , Zifeng Yang, M.D., Ph.D. ^{a,b,c,f*}
12	Affiliations
13	^a National Clinical Research Center for Respiratory Disease, State Key Laboratory of
14	Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated
15	Hospital of Guangzhou Medical University, Guangzhou, China
16	^b Guangzhou Laboratory, Guangzhou, China
17	° Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of
18	Infectious Diseases, KingMed School of Laboratory Medicine, Guangzhou Medical
19	University, Guangzhou, China
20	^d Huizhou Central People's Hospital, Huizhou, China
21	^e Department of Critical Care Medicine, Dongguan Institute of Respiratory and Critical
22	Care Medicine, Dongguan People's Hospital, Dongguan, China.

- ¹23 ^f State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for
- 24 Applied Research in Medicine and Health, Macau University of Science and
- 25 Technology, Taipa, Macau SAR, China
- ²⁶ ^g Vision Medicals Laboratory, Guangzhou, China
- 27 **Keywords:** Avian influenza A(H5N6) virus; baloxavir marboxil; viral load; sepsis;
- 28 cytokines
- 29 Running title: Baloxavir use in critical H5N6 patients
- ³⁰ [#]W.G., R.Q., L.S., K.M., W.P. and Z.L. contributed equally to this work.
- 31 ***Corresponding authors:** N.Z. and Z.Y. contributed equally to this work.
- 32 Zifeng Yang
- 33 National Clinical Research Center for Respiratory Disease, State Key Laboratory of
- Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated
- 35 Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou,
- 36 Guangdong, 510120, China.
- 37 Tel: 8620-83205181; Fax: 8620-83205181; E-mail: jeffyah@163.com
- 38
- 39 Nanshan Zhong
- 40 National Clinical Research Center for Respiratory Disease, State Key Laboratory of
- 41 Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated
- 42 Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou,
- 43 Guangdong, 510120, China.
- 44 Tel: 8620-83062868; Fax: 8620-83062868; E-mail: nanshan@vip.163.com

45 Author for backup contact before publicati

- 46 Weiqi Pan
- 47 National Clinical Research Center for Respiratory Disease, State Key Laboratory of
- 48 Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated
- 49 Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou,
- 50 **Guangdong**, **510120**, **China**.
- 51 Tel: 8620-83205181; Fax: 8620-83205181; E-mail: panweiqi@gird.cn
- 52

53 Author contributions

- 54 Conceived study: Zifeng Yang, Nanshan Zhong
- 55 Designed study and experiments: Wenda Guan, Rong Qu, Lihan Shen, Kailin Mai, Weiqi
- 56 Pan, Zhengshi Lin, Zifeng Yang, Nanshan Zhong
- 57 Performed experiments: Wenda Guan, Rong Qu, Lihan Shen, Kailin Mai, Weiqi Pan, Liping
- 58 Chen, Ji Dong, Jiawei Zhang, Pei Feng, Yunceng Weng, Minfei Yu, Peikun Guan, Jinchao
- 59 Zhou, Chuanmeizi Tu, Xiao Wu, Chunguang Yang, Yun Ling, Sheng Le, Yangqing Zhan, Yimin
- Li, Xiaoqing Liu, Heyan Zou, Ziqi Huang, Hongxia Zhou, Qiubao Wu, Wenjie Zhang, Jiayang
- 61 He, Teng Xu
- 62 Interpreted data: Kailin Mai, Weiqi Pan, Zhengshi Lin, Wenda Guan, Rong Qu, Lihan Shen,
- 63 Nanshan Zhong, Zifeng Yang
- 64

65 Highlights:

66 (1) Baloxavir potently decreased viral load in avian influenza H5N6 human infections.

67 (2) Preexisting conditions, extrapulmonary dysfunction and systemic inflammation
 68 determined prognosis of H5N6 patients.

(3) Indicator cytokines in sputum and serum reflecting ARDS and sepsis progression
 respectively, were identified in H5N6 patients.

71

Abstract

Background: Recent increase in human infections of highly pathogenic avian
 influenza H5N6 virus and its high mortality have raised concerns.

Methods: To analyze evolution of outcomes, longitudinal clinical data and specimens were collected from five patients infected with H5N6 virus after admission. All patients received antiviral treatment either sequentially or in combination of oseltamivir with baloxavir. Severity of illness, and viral load in sputum, urine and blood, and cytokine levels in serum and sputum were serially analyzed.

Results: When delayed oseltamivir showed poor effects on high respiratory viral 79 load, baloxavir was prescribed and viral load had a rapid reduction. All patients 80 developed acute respiratory distress syndrome (ARDS) and sepsis within one week 81 after disease onset, three patients died eventually. Nonsurvivors had more severe 82 preexisting condition, extrapulmonary organ dysfunction and insufficient H5N6 virus-83 specific antibody response. Grouped by delta SOFA on the sample collection date, 84 serum levels of IL-1α, IL-1β, IL-1RA, MIF, Mig, MIP-1α, IFN-γ, IL-12p40, IL-16, IL-18, 85 IL-2Ra, IL-6, basic FGF, G-CSF, HGF, M-CSF, SCF were identified as indicator 86 cytokines reflecting sepsis progression; and sputum levels of IL-18, IL-6, HGF, M-CSF 87 were indicators of ARDS progression. Comparisons of cytokine levels before, during 88

89	and after baloxavir treatment suggested that, baloxavir may also reduce a few
90	indicator cytokines in sputum and serum that related to viral load and multi-organ
91	dysfunction.
92	Conclusions: Baloxavir can effectively reduce viral load and few proinflammatory
93	cytokines associated with deterioration. However, disease outcome is determined by
94	severity of preexisting conditions and multi-organ dysfunction.
95	Keywords: Avian influenza A(H5N6) virus; baloxavir marboxil; viral load; sepsis;
96	cytokines
97	An update version of this manuscript is under revision in <i>Med</i> from Cell Press.
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	

111

Text

112 Introduction

Human infection with avian influenza A viruses can cause severe diseases, in which 113 highly pathogenic avian influenza (HPAI) A viruses often induce fulminant pneumonia 114 and multi-organ failure. The first outbreak of zoonotic avian influenza A viruses in 115 human occurred in Hong Kong in 1997, with 6 deaths in 18 cases resulted from highly 116 pathogenic avian influenza (HPAI) A subtype H5N1 virus infection [1]. As of January 117 2023, H5N1 infections have caused at least 868 human cases with 457 deaths 118 worldwide (case fatality rate [CFR], 52.6%) [2]. Since 2013, continued reassortment 119 of H5N1 viruses has generated multiple subtypes [3], in which novel HPAI H5N6 120 viruses of clade 2.3.4.4 have recently become the dominant H5 lineage circulating in 121 122 China [4]. After the first case reported in 2014, most H5N6 human infections occurred in China, except for one case reported from Laos in 2021 [5]. As of 10 March 2023, 123 totally 84 cases and 33 deaths of H5N6 human infection were reported globally (CFR, 124 39.3%) [6], in which 36 cases and 22 cases arose in 2021 and 2022, respectively, and 125 such increase of human HPAI infection seems to continue [4, 7], posing potential public 126 health threat. 127

Human H5N6 infections commonly initiated with fever and cough, which were difficult to distinguish from other respiratory infection at early stage [4, 8], and subsequently acute respiratory distress syndrome (ARDS), sepsis and multiple organ dysfunction (MOD) rapidly progressed [9, 10]. High viral load, prolonged viral shedding, and the elicited intense inflammatory response are central to the pathogenesis of HPAI human infections [11, 12], hence early antiviral treatment and timely immunomodulatory
 therapy play a crucial role in clinical management. However, the longitudinal viral and
 immunological associations with disease outcome remain unclear.

Neuraminidase inhibitors (NAI), usually oseltamivir monotherapy, has survival benefit 136 for H5N1 and H7N9 patients especially when treatment initiated early in the clinical 137 course [13, 14]. On the other hand, delayed NAI treatment proved to be an 138 independent risk factors of prolonged viral shedding and NAI combination therapy 139 could not reduce shedding duration in H7N9 patients [15]. Baloxavir marboxil is a novel 140 small-molecule cap-dependent endonuclease inhibitor targets influenza polymerase 141 acidic protein subunit, which has greater antiviral effects against influenza virus than 142 oseltamivir, both in mouse models and uncomplicated influenza patients [16, 17]. 143 Furthermore, baloxavir exhibits better antiviral effects and protection against lethal 144 challenge compared with oseltamivir in lethal mouse models of avian influenza virus 145 H7N9 [18] and H5N1 [19]. However, the effectiveness of baloxavir against HPAI 146 human infection remains unknown. 147

Here, we reported five laboratory-confirmed human infection cases with avian H5N6 virus discovered in Guangdong province, China. All these patients received antiviral treatment using either sequentially or in combination of oseltamivir with baloxavir. We discovered indicator cytokines reflecting ARDS or sepsis progression and their correlations with viral load, virus-specific serological response and disease severity were analyzed. To evaluate potential effects of baloxavir, levels of indicator cytokines were compared before, during, and after treatment.

155

156 Methods

157 Design overview and participants

Five patients with laboratory-confirmed H5N6 virus infection between August 2021 and July 2022 in Guangdong Province, China, were included. As previously described, infection of avian influenza A(H5N6) virus was confirmed by metagenomic nextgeneration sequencing(mNGS) [4], reverse-transcriptase polymerase chain reaction (RT-PCR) assay [20] and serologic testing of hemagglutination inhibition assay and microneutralization assay [21]. Details of laboratory diagnosis are provided in the Supplementary Appendix.

The study was approved by ethical committees of The First Affiliated Hospital of Guangzhou Medical University (Ethics No. 2016-78). Written consents have been signed by the patients or their family members for collecting samples and clinical data for this study.

169

170 Clinical data and sample collection

Medical records of five patients were collected and reviewed by a team of physicians who had clinical experience with avian influenza. Samples of different time points from each H5N6 patient were collected according to actual clinical situation, in which blood, throat swabs, sputum and bronchoalveolar lavage fluid (BALF) were accessible from all patients, while urine samples were able to obtain from patient 1, 2, 3 and 5.

Identification and characterization of H5N6 virus from patients' respiratory samples 177 Details of methods used to identify and characterize the H5N6 virus were provided in 178 the Supplementary Appendix. Briefly, BALF samples from five patients were used for 179 mNGS analysis; the eight gene fragments of H5N6 virus were amplified by 180 conventional RT-PCR (Supplementary Table 1) and the PCR product was purified and 181 sequenced. The H5N6 viral load was measured on sputum, throat swabs, peripheral 182 blood and urine samples from the patients. Viral RNAs were extracted from heat 183 inactivated clinical samples using the QIAamp Viral RNA Kit (Qiagen) in a biosafety II 184 laboratory. Quantitative detection of viral nucleic acid in the above samples was then 185 performed using the Detection Kit for Influenza A virus RNA (HUARUIAN BIOLOGY) 186 and analyzed simultaneously according to the manufacturer's instruction. 187

188

189 Measurements of sequential organ failure assessment score

To quantify severity of organ dysfunction in H5N6 patients, admission and daily 190 maximum Sequential Organ Failure Assessment (SOFA) [22, 23] was scored and 191 reviewed by the team of experienced physicians as mentioned above. During 192 assessment, some principles [24] were followed to ensure applicability and 193 consistency, and details were provided in the Supplementary Appendix and 194 Supplementary Table 2. Sepsis was diagnosed with SOFA score above two[22]. Delta 195 SOFA score was calculated as the change of SOFA score from admission to the 196 defined time point. 197

198

199 **Definitions**

The time of disease onset was defined as the date of influenza-like illness (ILI) onset 200 (fever and cough or sore throat) or other acute-onset signs or symptoms (e.g., fatigue 201 and dyspnea) consistent with influenza illness, which was designated as day 0 after 202 onset (D0). For dynamic measurements, the time of viral load, SOFA scores, cytokines 203 and other laboratory indices were calculated from disease onset to the sample/data 204 collection date. Viral shedding duration referred to the time from disease onset to the 205 last positive result on RT-qPCR tests, in which threshold cycle values above 35 was 206 207 defined as negative results. Definitions of pneumonia, ARDS and acute kidney injury are provided in the Supplementary Appendix. 208

209

210 Antiviral treatment

NAI therapy (oseltamivir) was given according to local clinical practice. Baloxavir was administered when respiratory viral load remained above 5 \log_{10} copies/mL after at least 4 days of NAI treatment, as 40 mg (for 40 kg to <80 kg bodyweight) or 80mg (for \geq 80 kg bodyweight) enterally for every 3 days and terminated when influenza viral RNA was negative. Patient 1 and patient 4 received oseltamivir-baloxavir sequential treatment because of severe renal failure, and other patients received oseltamivirbaloxavir combined treatment (Table 1).

218

219 Cytokine measurements

220 Sputum and serum samples of five patients were collected at multiple time points after

hospitalization (Supplementary Table 3 and Supplementary Figure 1). Protein
concentrations of 48 cytokines in sputum supernatants and serum were measured
using the Bio-Plex Pro Human Cytokine Screening 48-Plex Panel on the Bio-Plex 200
Multiplex Testing System (Bio-Rad) following manufacturer instructions.

225

226 Statistical analysis

Correlations between cytokines, viral load and clinical parameters were assessed by 227 Spearman's correlation tests. Serum cytokines at multiple time points from five 228 229 patients were bulked and grouped according to delta SOFA at the corresponding time points, which included delta SOFA \geq 0 or delta SOFA <0. Sputum cytokines were 230 grouped by delta SOFA respiration sub-scores. Cytokine levels between groups were 231 232 compared and significance was determined by Wilcoxon rank-sum tests. GraphPad Prism 9.0, R package corrplot (https://cran.r-project.org/web/packages/corrplot/) and 233 ggpubr (https://cran.r-project.org/web/packages/ggpubr/) were used for analysis. 234

235

236 **Results**

Features of epidemiology, clinical manifestation and laboratory abnormalities in H5N6
 virus infected patients

All five patients had contact history with poultry that had no signs of HPAI infection (Table 1). Patients with more severe underlying conditions (patient 1 and 4) had backyard-raised chickens, and the others with less severe chronic illness worked in the farmers' market. Nonsurvivors had major comorbidities of hypertension (patient 1,

3 and 4), diabetes (patient 1 and 4), and chronic obstructive pulmonary disease 243 (COPD, patient 4). All patients initially presented with ILI symptoms and quickly 244 developed into dyspnea and ARDS (PaO₂/FiO₂ <300) within one week, requiring 245 invasive mechanical ventilation. With SOFA score above two, sepsis was diagnosed 246 in five patients on ICU admission and as hypoxemia worsened, extracorporeal 247 membrane oxygenation was administered in four patients (Figure 1A-1E and 248 Supplementary Figure 1). As fulminant pneumonia developed, influenza was firstly 249 suspected. However, with continuously searching for causative pathogens, avian 250 251 influenza A (H5N6) virus wasn't found in the patients' respiratory tracts until mNGS on BALF (Supplementary Appendix). Phylogenetic analysis showed that the 252 hemagglutinin (HA) genes of H5N6 virus derived from all five patients belonged to 253 254 clade 2.3.4.4, whereas the neuraminidase genes (NA) belonged to Major clade among H5N6 serotypes [25] (Supplementary Figure 2). Serological analysis further confirmed 255 the diagnosis (Figure 1F-1J). 256

257 Three patients required renal replacement therapy because of preexisting diabetic nephropathy (patient 1) and acute kidney injury arose (patient 3 and 4). Intravenous 258 corticosteroids were prescribed in all patients, in which patient 3 and 5 were given 259 more than once. Characteristics of laboratory measurements in five patients were 260 summarized in Supplementary Table 4. Serum creatinine in patient 1, 3 and 4 elevated 261 on admission, suggesting renal dysfunction. In patient 1, 2, 3 and 5, bacterial infection 262 was confirmed by positive sputum or blood culture results after at least 10 days of viral 263 RNA detection. Three patients had bacteria cultured in sputum and multidrug-resistant 264

bacteria emerged in patient 1 and patient 5. Staphylococcus epidermidis septicemia
 presented in patient 3. After at least 30 days in ICU, patient 1, 3 and 4 died from sepsis
 and multiple organ failure, and patient 2 and 5 survived.

Compared with survivors, nonsurvivors (patient 1, 3 and 4) had more dysfunctional
organs involved, dominated by respiratory, cardiovascular and renal systems, in which
SOFA scores gradually increased and endured until death (Figure 1A, 1C and 1D).
Moreover, nonsurvivors had relatively low or delayed antibody response (Figure 1F,
1H and 1I).

273

274 Antiviral effects of baloxavir treatment

High viral load (above 5 log₁₀ copies/mL) was detected in sputum from all patients, 275 276 while viral load in throat swabs was relatively low (Figure 2). For patient 2, viral RNA was detected in urine and duration of urine viral shedding was 25 days (Figure 2B). 277 The median time from disease onset to oseltamivir prescription was 5 days for five 278 279 patients (Table 1 and Supplementary Figure 1). Considering high sputum viral load and relatively poor effects of delayed NAI usage [12], baloxavir marboxil [17, 26] was 280 prescribed. Median time from disease onset to baloxavir prescription was 11 days. In 281 4 patients (patient 1, 2, 3 and 4), median sputum viral load was above 5 log₁₀ 282 copies/mL after 5 days of double-dose oseltamivir, but was enormously reduced after 283 baloxavir prescription, with over 200-fold reduction on average after twice baloxavir 284 prescriptions (Figure 2A-2D). Median viral shedding duration of all patients was 22 285 days. Patient 5 who survived, had the shortest duration of viral shedding (16 days); 286

the time from disease onset to baloxavir prescription was 7 days, which was the
earliest initiation of baloxavir usage among five patients (Table 1 and Figure 2E).
These results suggested that usage of baloxavir can potently and rapidly decrease the
viral load in H5N6 patient even at the later stage of disease.

Associations between viral dynamics with severity of hypoxemia and sepsis were analyzed respectively (Supplementary Figure 3). Statistically significant correlations between viral load with both PaO₂/FiO₂ ratio and SOFA scores were only found in two patients, indicating that H5N6 viral load in airways may not be a sole determinant for hypoxemia development and vital organ damage.

296

297 Identification of indicator cytokines and the effect of baloxavir on their levels

For further investigation on immunological response, sputum and serum samples were collected from five patients to measure cytokine levels throughout their disease trajectories (Supplementary Figure 4 and 5). Strong and comparable correlation intensities were observed between sputum cytokines in survivors and nonsurvivors; however, serum cytokines were more pronounced in nonsurvivors than in survivors (Supplementary Figure 6).

Delta SOFA has been recommended in clinical practice [27] to dynamically evaluate severity of sepsis and organ dysfunction for its reliable association with mortality and low degrees of heterogeneity [24]. To discover cytokines with potential value of dynamic assessment, we first classified sampling timepoints as disease progression or regression by delta SOFA \ge 0 or delta SOFA < 0 (Figure 3A). Cytokines with

statistically significant differences between two kinds of timepoints were identified as 309 indicator cytokines, which could reflect disease status of H5N6 patients. Among 48 310 cytokines, we found 4 cytokines in sputum and 18 cytokines in serum as indicators of 311 ARDS progression and sepsis progression, respectively. Sputum IL-18, IL-6, HGF, M-312 CSF significantly elevated when ARDS deteriorated (Figure 3B). Serum IL-1 α , IL-1 β , 313 IL-1RA, MIF, Mig, MIP-1α, IFN-γ, IL-12p40, IL-16, IL-18, IL-2Rα, IL-6, basic FGF, G-314 CSF, HGF, M-CSF, SCF significantly increased, Eotaxin significantly decreased when 315 sepsis deteriorated (Figure 3C). 316

317 Next, we analyzed correlations between indicator cytokines with days after disease onset (D.A.O), viral load, serum antibody titers and SOFA scores, respectively. Levels 318 of indicator cytokines in sputum were all positively correlated with sputum viral load 319 320 and SOFA scores, and HGF significantly decreased over D.A.O (Figure 4A). Except for IL-12p40 and G-CSF, all indicator cytokines in serum had positive correlation with 321 SOFA scores, and the majority also had positive correlations with renal sub-scores 322 (Figure 4B). Serum Mig and IL-18 were positively correlated with viral load, SOFA 323 scores and four sub-scores, while IL-18 significantly decreased over D.A.O. Besides, 324 lower titers of virus-neutralizing antibody correlated with higher IL-6 and IL-1ß levels 325 in serum. To evaluate impacts of baloxavir on indicator cytokine levels, sampling 326 timepoints were divided as before/during/after baloxavir treatment, and the alterations 327 in cytokine levels were compared. All 4 indicator cytokines in sputum significantly 328 decreased after baloxavir treatment (Figure 4C). However, only Mig and IL-18 329 statistical-significantly decreased in serum indicator cytokines after baloxavir 330

treatment (Figure 4D). The above results suggested that, indicator cytokines could reflect the disease status of H5N6 patients, correlating with viral load, antibody response, and MOD. Baloxavir predominantly reduced respiratory inflammatory response, but also could reduce a few systemic cytokines related to MOD, which may be partially attributed to its antiviral effect.

336

337 Discussion

Limited by case numbers, previous summary of H5N6 human cases focused on 338 comparisons with other influenza A virus infections [28] and lacked longitudinal data 339 regarding disease pathogenesis. Our results revealed that, patients with underlying 340 chronic illness was predisposed to H5N6 infection, which were also associated with 341 342 fatality in influenza A(H1N1)pdm09 [29] and avian A(H7N9) [30] infections. H5N6 patients suffered from rapidly progressed and refractory sepsis, a life-threatening 343 syndrome that mostly triggered by infection and characterized as systemic immune 344 chaos with multi-organ failures [31]. Bacteria is frequently associated with sepsis 345 development [32], yet viral sepsis has attracted attention for its high prevalence in 346 COVID-19 [33]. The fact that sepsis developed in all H5N6 patients without evidence 347 of bacterial infection within the first two weeks leads to a suspicion that it was triggered 348 by high viral load, since influenza A virus was mostly detected in viral pneumonia-349 related sepsis [34]. Host immune response to influenza shares some common 350 351 pathways with the response to bacteria [35, 36] might be an explanation. On the other hand, both seasonal and avian influenza infection were highly predisposed to bacterial 352

infection, which is the leading cause of clinical deterioration [30, 36]. Positive cultures
and elevated PCT revealed that, bacterial infections developed in all H5N6 patients
after LRT viral load decreased and augmented organ dysfunction [32]. We proposed
that H5N6 virus exacerbated underlying chronic illness and subsequently induced
MOD, leading to poor outcomes.

As the incidence of HPAI infections in human rises [4], the search for more effective 358 antiviral and immunomodulatory therapy becomes urgent. This is the first report of 359 baloxavir for antiviral treatment in avian influenza human infection. Consistent with 360 studies on severe influenza patients [26], baloxavir-NAI combination exhibited potent 361 antiviral effect without outcome advantage. Our results showed that baloxavir could 362 potentially decrease lung inflammation in H5N6 human infections, compatible with the 363 364 efficacy in H5N1 murine models [19], yet had limited influence on serum cytokines. Inadequate virus-specific serological response and hypercytokinemia may account for 365 such unsatisfactory outcome, raising the possibility of using antibody-based treatment 366 and immune modulators. In our data, the patient who took baloxavir within one week 367 after illness onset had the shortest duration of viral shedding and survived, even with 368 intravenous corticosteroids prescription that could prolong viral clearance [37], 369 suggesting the coordination of potent antivirals and immune modulators has potential 370 371 therapeutic benefit for extreme circumstances of avian influenza human infections.

While most cytokines in respiratory tract decreased with time and viral load, systemic inflammation dominated in H5N6 patients. Among the serum indicator cytokine profiles we discovered, IL-6, M-CSF and HGF have been previously identified as markers

reflecting organ damage in severe COVID-19 patients [38]. Notably, taking together 375 both our results and previous comparisons of serum cytokine profiles between H5N6, 376 H7N9 and H1N1 patients [28], we speculate that serum IL-2Rα, IL-12p40 and M-CSF 377 play pivotal roles in H5N6-induced sepsis and could be biomarkers of critical cases. 378 Increased concentration of serum IL-2Ra is the result of T-cell activation [39], while IL-379 12p40 mainly acts as chemoattractant and M-CSF is colony-stimulating factor both for 380 macrophages. Hypercytokinemia in H5N6 patients suggests the potential role of anti-381 cytokine antibodies and cytokine modulators [40], such as IL-6 receptor blockade and 382 Janus kinase inhibitors [41]. 383

It is also interesting to note that H5N6 virus RNA was detected in urine from one 384 survivor (patient 2), while no evidence of viremia or renal dysfunction presented. This 385 386 is the first report on urine viral shedding in H5N6 patients, which has been previously found in human infected with influenza A(H7N9) virus [42]. No association between 387 urine viral RNA detection and renal dysfunction could be possibly accounted for 388 hematogenous dissemination through infected lymphocytes or macrophages [42, 43]. 389 There are limitations in this research. Case numbers were constrained by the sporadic 390 occurrence of H5N6 human infections. As a retrospective summary of five cases, 391 influence of systemic corticosteroids on secondary bacterial infection and outcome 392 was unclear, which could also confound the cytokine profile analysis, remaining an 393 ongoing challenge. While our case study provides some insights on antiviral treatment 394 for HPAI human infections, the variability in patients and approach makes it difficult to 395 draw string conclusions and therefore highlights the need for a prospective hypothesis 396

driven study. It is interesting to investigate whether the initiation of baloxavir prescription as early as possible once patients show influenza-like symptoms in an HPAI endemic area, and the application of immunomodulators when hypercytokinemia develops, could lower the CFR of HPAI human infections.

401 **Conclusion**

In summary, our study illustrates that for human infection with H5N6 virus, baloxavir can effectively reduce viral load and prevent pulmonary deterioration even at the later stage of disease. However, preexisting conditions, extrapulmonary dysfunction and systemic inflammation are potential determinants of the disease outcomes.

406

407 **Notes**

408 *Acknowledgements.* We thank Vision Medicals Laboratory and Guangzhou 409 Huayin Medical Laboratory Center Co., Ltd. for their technical support on 410 metagenomic next-generation sequencing. Also, we would like to thank Dr. Faqiang 411 He, Dr. Zhipeng Li, Dr. Ruiyu Lu, Dr. Hanmian Liu, Dr. Yongli Wu, Dr. Zhihui Zhuang, 412 and the ICU teams for taking care of the patients.

413 **Disclaimer.** The funders had no role in the study design, results, interpretation, or 414 decision to submit the manuscript for publication.

Financial support. This work was supported by the National Natural Science Foundation of China (grant number 81761128014). Z.Y. received support from Guangzhou Institute of Respiratory Health Open Project (funds provided by China Evergrande Group, grant number 2020GIRHHMS01) and Zhongnanshan Medical

Foundation of Guangdong Province (grant number ZNSA-2020013). W.G. reported 419 funding from Guangzhou Science and Technology Program (grant number 420 202102100003), Open Project of State Key Laboratory of Respiratory Disease (grant 421 number SKLRD-OP-202001) and Guangdong-Hong Kong-Macao Joint Laboratory of 422 Respiratory Infectious Diseases Funding Project (grant number GHMJLRID-Z-423 202105). W.P. received support from the National Natural Science Foundation of 424 China (grant number 31970884). L.S. and H.Z. reported funding from Guangdong 425 Basic and Applied Basic Research Foundation (grant number 2020B1515120045 and 426 427 2020A1515110151).

428 **Potential conflicts of interest.** All authors declare that they have no known 429 competing financial interests or personal relationships that could have influenced the 430 work reported in this paper.

431

432 **Reference**

433 1. Chan PKS. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin
434 Infect Dis 2002; 34 Suppl 2:S58-S64.

World Health Organization. Cumulative number of confirmed human cases for avian
influenza A(H5N1) reported to WHO, 2003-2023, 5 January 2023. Available at:
https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-

438 avian-influenza-a(h5n1)-reported-to-who-2003-2022-5-jan-2023.

439 3. Claes F, Morzaria SP, Donis RO. Emergence and dissemination of clade 2.3.4.4 H5Nx

440 influenza viruses-how is the Asian HPAI H5 lineage maintained. Curr Opin Virol 2016; 16:158-

441 **63**.

- 442 4. Zhu W, Li X, Dong J, et al. Epidemiologic, Clinical, and Genetic Characteristics of Human
 443 Infections with Influenza A(H5N6) Viruses, China. Emerging Infectious Disease journal 2022;
 444 28:1332.
- 5. World Health Organization Western Pacific Region. Avian influenza weekly update number
- 446 785, 26 March 2021. Available at: http://apps.who.int/iris/bitstream/handle/10665/341148/AI-
- 447 20210326.pdf?sequence=209&isAllowed=y.
- 6. World Health Organization Western Pacific Region. Avian influenza weekly update number
- 449 886, 10 March 2023. Available at: https://apps.who.int/iris/bitstream/handle/10665/365675/AI-
- 450 **20230310.pdf?sequence=76&isAllowed=y**.
- 451 7. Chen J, Xu L, Liu T, et al. Novel Reassortant Avian Influenza A(H5N6) Virus, China, 2021.
- 452 Emerg Infect Dis **2022**; 28:1703-7.
- 453 8. Uyeki TM, Peiris M. Novel Avian Influenza A Virus Infections of Humans. Infect Dis Clin
- 454 North Am **2019**; 33:907-32.
- 455 9. Feng Y, Guan W, Yuan B, et al. Emergence of triple-subtype reassortants of fatal human
- 456 H5N6 avian influenza virus in Yunnan, China. J Infect **2016**; 72:753-6.
- 457 10. Yang Z-F, Mok CKP, Peiris JSM, Zhong N-S. Human Infection with a Novel Avian Influenza
- 458 A(H5N6) Virus. N Engl J Med **2015**; 373:487-9.
- 459 11. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1)
- is associated with high viral load and hypercytokinemia. Nat Med **2006**; 12:1203-7.
- 12. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease
- 462 caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of

- 463 antiviral resistance. Lancet **2013**; 381:2273-9.
- 464 13. Chan PKS, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza
 465 virus A subtype H5N1. J Infect Dis **2012**; 206:1359-66.
- 466 14. Zheng S, Tang L, Gao H, et al. Benefit of Early Initiation of Neuraminidase Inhibitor
- 467 Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. Clin Infect Dis 2018;
 468 66:1054-60.
- 15. Wang Y, Guo Q, Yan Z, et al. Factors Associated With Prolonged Viral Shedding in Patients
- 470 With Avian Influenza A(H7N9) Virus Infection. J Infect Dis **2018**; 217:1708-17.
- 16. Fukao K, Noshi T, Yamamoto A, et al. Combination treatment with the cap-dependent
- 472 endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of

473 influenza A virus infection. J Antimicrob Chemother **2019**; 74:654-62.

- 17. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in
- 475 Adults and Adolescents. N Engl J Med **2018**; 379:913-23.
- 18. Taniguchi K, Ando Y, Nobori H, et al. Inhibition of avian-origin influenza A(H7N9) virus by
- the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep **2019**; 9:3466.
- 19. Taniguchi K, Ando Y, Kobayashi M, et al. Characterization of the In Vitro and In Vivo
- 479 Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
- 480 Viruses **2022**; 14.
- 481 20. Heine HG, Foord AJ, Wang J, et al. Detection of highly pathogenic zoonotic influenza virus
- 482 H5N6 by reverse-transcriptase quantitative polymerase chain reaction. Virol J **2015**; 12:18.
- 483 **21.** Department of Communicable Disease Surveillance and Response WHO. WHO manual
- 484 on animal influenza diagnosis and surveillance. Available at:

485 https://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf.

- 486 22. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
 487 Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801-10.
- Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure
 Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on
 Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care
- 491 Med **1996**; 22:707-10.
- 492 24. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and
- 493 challenges of accurate assessment in clinical trials. Crit Care **2019**; 23:374.
- 494 25. Bi Y, Chen Q, Wang Q, et al. Genesis, Evolution and Prevalence of H5N6 Avian Influenza
 495 Viruses in China. Cell Host Microbe **2016**; 20:810-21.
- 496 26. Kumar D, Ison MG, Mira J-P, et al. Combining baloxavir marboxil with standard-of-care
 497 neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a
 498 randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect
 499 Dis 2022; 22:718-30.
- 500 27. de Grooth H-J, Geenen IL, Girbes AR, Vincent J-L, Parienti J-J, Oudemans-van Straaten
- 501 HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and
- 502 meta-regression analysis. Crit Care **2017**; 21:38.
- 28. Bi Y, Tan S, Yang Y, et al. Clinical and Immunological Characteristics of Human Infections
 With H5N6 Avian Influenza Virus. Clin Infect Dis **2019**; 68:1100-9.
- 505 29. Singanayagam A, Singanayagam A, Wood V, Chalmers JD. Factors associated with
- severe illness in pandemic 2009 influenza a (H1N1) infection: implications for triage in primary

- 507 and secondary care. J Infect **2011**; 63:243-51.
- 30. Zheng S, Zou Q, Wang X, et al. Factors Associated With Fatality Due to Avian Influenza
 A(H7N9) Infection in China. Clin Infect Dis 2020; 71:128-32.
- 510 31. Gu X, Zhou F, Wang Y, Fan G, Cao B. Respiratory viral sepsis: epidemiology,
- 511 pathophysiology, diagnosis and treatment. European Respiratory Review **2020**; 29:200038.
- 512 32. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of
- sepsis and potential therapeutic targets. Nat Rev Immunol **2017**; 17:407-20.
- 33. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, et al. Coronavirus Disease 2019 as
- 515 Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. Crit Care Med 2021; 49:2042-
- 516 **57**.
- 517 34. Cillóniz C, Dominedò C, Magdaleno D, Ferrer M, Gabarrús A, Torres A. Pure Viral Sepsis
- 518 Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors. J Infect
- 519 Dis **2019**; 220:1166-71.
- 35. Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The
 role of microvascular permeability: A review of mechanisms and methods. Antiviral Res 2012;
 93.
- 523 **36**. Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and 524 epidemiology. Crit Care **2019**; 23:258.
- 37. Cao B, Gao H, Zhou B, et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A
 (H7N9) Viral Pneumonia. Crit Care Med **2016**; 44:e318-e28.
- 527 38. Quartuccio L, Fabris M, Sonaglia A, et al. Interleukin 6, soluble interleukin 2 receptor alpha
- 528 (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic

- 529 hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 530 pneumonia. Cytokine **2021**; 140:155438.
- 531 **39.** Damoiseaux J. The IL-2 IL-2 receptor pathway in health and disease: The role of the
- soluble IL-2 receptor. Clinical Immunology **2020**; 218:108515.
- 40. Elbahesh H, Gerlach T, Saletti G, Rimmelzwaan GF. Response Modifiers: Tweaking the
- Immune Response Against Influenza A Virus. Front Immunol **2019**; 10:809.
- 41. Hays L, Black M, Prunty M, et al. Could treatment with immunomodulatory agents targeting
- 536 IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia?
- 537 A systematic and narrative review. HRB Open Research **2022**; 5:77.
- 42. Zhu Z, Liu Y, Xu L, et al. Extra-pulmonary viral shedding in H7N9 Avian Influenza patients.
- 539 J Clin Virol **2015**; 69:30-2.
- 43. Chan MCW, Lee N, Chan PKS, et al. Seasonal influenza A virus in feces of hospitalized
- adults. Emerg Infect Dis **2011**; 17:2038-42.
- 542
- 543
- 544
- 545
- 546
- 547
- 548
- 549

550 Table 1. Epidemiologic and clinical characteristics of human infections with avian influenza A H5N6 virus in Guangdong Province, China from 2021 to 2022

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5			
Age ranges	51-55	51-55	51-55	66-70	41-45			
Sex	Female	Male	Male	Male	Female			
Place of residence	Guangdong Province	Guangdong Province	Guangdong Province	Guangdong Province	Guangdong Province			
Contact history with poultry	Backyard-raised chickens	Worked in a farmers' market	Worked in a farmers' market	Backyard-raised chickens	Worked in a farmers' market			
	Hypertension, diabetes and	Chronic bronchitis and anterior		Hypertension, diabetes,				
Underlying conditions		mediastinal teratoma	Hypertension	emphysema, and duodenal	No			
	diabetic nephropathy			ulcers, pancreatic tumor				
Long-term smoker	No	Yes	No	No	No			
Duration of symptoms before	2	r	0	4	4			
hospitalization	3	5	3	4	4			
		Opurely former for the	Cough, hemoptysis, fever, headache,	Melena, fatigue, fever, dyspnea,				
Presenting symptoms	Asthenia, fever, dyspnea	Cough, fever, fatigue, dyspnea	fatigue, dyspnea	jaundice	Cough, fever, dyspnea			
SOFA score on ICU admission	7	11	8	4	8			
Baseline serologic response	D21,	D8,	D10,	D9,	D8,			
(time of sample collection, titers)	HAI 1:20, MN 1:20	HAI 1:20, MN 1:10	HAI 1:20, MN 1:20	HAI 1:10, MN 1:10	HAI 1:20, MN 1:40			
Complications*								
Pulmonary	Pneumonia, ARDS	Pneumonia, ARDS	Pneumonia, ARDS	Pneumonia, ARDS	Pneumonia, ARDS			
Extrapulmonary	Sepsis	Sepsis	Sepsis, acute kidney injury	Sepsis, acute kidney injury	Sepsis			
Advanced life support								
(time of initiation†, duration days)								
Invasive mechanical ventilation	D11, 42 days	D6, 36 days	D5, 75 days	D5, 31 days	D4, 177 days			
ECMO	D15, 11 days	D6, 25 days	D6, 74 days	NA	D18, 43 days			
Antiviral treatment								
(time of given+, dosage)								
Oseltamivir	D18-D27, 150 mg every 12h	D5-D31, 150mg every 12h	D5-D31, 150mg every 12h	D5-D11, 150 mg every 12h; D20-D25, 75 mg every 12h	D4-D24, 150 mg every 12h			
Baloxavir	D28, D31, D34, 40 mg	D12, D15, D18, D21, D24, 40mg	D10, D13, D16, D19, 80 mg	D11, D14, D17, 40 mg	D7, D10, D13, D16, 40 mg			
			D4-D5, Methylprednisolone 40mg;		D4-D8, Methylprednisolone 40mg every 12h;			
Intravenous corticosteroids			D15, D17, Dexamethasone 5mg;		D18, Methylprednisolone 40mg;			
(time of given+, type and dosage)	D13, Dexamethasone 5mg	D12, Dexamethasone 5mg	D23, D25, D27, D32, Dexamethasone	D4, Methylprednisolone 40mg	D55, Dexamethasone 5mg;			
			10mg		D69, D77, D79, D80, Methylprednisolone 4			
Duration of viral shedding‡ (days)	38	24	20	22	16			
Duration of ICU stay (days)	50	45	75	31	189			
Outcome	Succumbed	Survived	Succumbed	Succumbed	Survived			
Definitions of pneumonia ARDS and	acute kidnev iniury are provided ir	the Supplementary Appendix. Sepsis wa	s diagnosed with SOFA score above two					

551 "Definitions of pneumonia, ARDS and acute kidney injury are provided in the Supplementary Appendix. Sepsis was diagnosed with SOFA score above two. ⁵⁵² †Time points are presented as numbers of days after disease onset. The date of illness onset was identified as day 0 after disease onset (D0), and the subsequent dates were calculated successively. ‡Duration of viral shedding referred to duration days from disease onset to the last positive PCR results, in which negative results were defined as threshold cycle values above 35. 553 Abbreviation: ICU, intensive care units; HAI, hemagglutination inhibition assay; MN, micro-neutralization assay; ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation.

555	Figure legends
556	
557	Figure 1. Figure 1. Dynamic change of SOFA scores and virus-specific serologic
558	response in five H5N6 patients.
559	A-E, Area charts show the temporal variations in daily maximum SOFA scores and
560	sub-scores of five patients.
561	F-J, Hemagglutinin inhibition (HAI) and microneutralization (MN) antibody titers of
562	serum samples from patients at different time points after disease onset. HAI titers
563	(blue circle) and neutralization titers (red square) are detected via recombinant (6+2)
564	DG/H5N6-PR8 virus.
565	
566	Figure 2. Dynamic change of viral load in five H5N6 patients.
567	A-E, Viral dynamics and antiviral treatment. Respiratory viral load at different time
568	points are marked by cross signs (throat swabs) and black asterisks (sputum). Viral
569	load in urine from patient 2 are marked by gray asterisks. Filling color of light orange
570	represents duration of oseltamivir prescription. Filling color of yellow represents
571	duration of baloxavir prescription (one dose every 3 days), with or without oseltamivir.
572	Abbreviation: OSE, oseltamivir; BAX, baloxavir.
573	
574	Figure 3. Comparison of cytokine levels during illness regression and
575	progression to identify indicator cytokines
576	A, Analysis workflow of identifying indicator cytokines that potentially reflect ARDS or 27

sepsis progression. Serum samples collected at multiple time points from five patients 577 are grouped according to delta SOFA at the corresponding time points, sputum 578 samples are grouped by delta SOFA respiration sub-scores. Delta SOFA is calculated 579 by the change of SOFA scores/sub-scores from admission to the specific time point 580 (detailed methods in Supplementary Appendix). At the sample collection date, delta 581 SOFA ≥0 indicated disease progression, and delta SOFA < 0 indicated disease 582 regression, respectively. And sputum/serum cytokine levels were compared between 583 two kinds of disease status. 584

B, Indicator cytokines in sputum. Box and jitter plots of sputum cytokine levels at ARDS regression (delta SOFA respiration sub-score on the collection date < 0, light blue, samples n=23) compared with those at ARDS progression (delta SOFA respiration sub-score on the collection date \ge 0, dark blue, samples n=45), with raw values plotted on the log10 scale.

590 C, Indicator cytokines in serum. Box and jitter plots of serum cytokine levels at sepsis 591 regression (delta SOFA on the collection date < 0, orange, samples n=11) compared 592 with those at sepsis progression (delta SOFA on the collection date \ge 0, red, samples 593 n=25), with raw values plotted on the log10 scale.

594 Medians and interquartile ranges were presented. Dots represented individual data at 595 different time points. Significance was determined by Wilcoxon rank-sum tests. *P* 596 values: * P<0.05, ** P<0.01, *** P<0.001.

597 Abbreviation: ARDS, acute respiratory distress syndrome.

599 Figure 4. Correlation of indicator cytokine levels with viral load, clinical 600 parameters and effect of baloxavir treatment

A, Heatmap showing correlation of sputum indicator cytokines with days after onset, sputum viral load, PaO₂/FiO₂ and SOFA scores. Significance was determined by Spearman's correlation tests.

B, Heatmap showing correlation of serum indicator cytokines with days after onset,
sputum viral load, SOFA scores and sub-scores. Significance was determined by
Spearman's correlation tests.

607 C, Effect of baloxavir treatment on sputum indicator cytokines. Box and jitter plots of

608 indicator cytokine levels in sputum before, during and after baloxavir treatment (n=16,

609 31, 21, respectively). Significance was determined by Wilcoxon rank-sum tests.

D, Effect of baloxavir treatment on serum indicator cytokines. Box and jitter plots of

611 indicator cytokine levels in serum before, during and after baloxavir treatment (n=7,

12, 17, respectively). Significance was determined by Wilcoxon rank-sum tests.

613 *P* values: * *P*<0.05, ** *P*<0.01, *** *P*<0.001, **** *P*<0.0001.

614 Abbreviation: D.A.O, days after disease onset; BAX, baloxavir.

615







Figure 1. Dynamic change of SOFA scores and virus-specific serologic response in five H5N6 patients



A. Analysis workflow



B. Sputum cytokines



C. Serum cytokines




Figure 3. Comparison of cytokine levels during illness regression and progression to identify indicator cytokines

Figure 4. Correlation of indicator cytokine levels with viral load, clinical parameters and effect of baloxavir treatment

																*		D.A.O
	*								*							***	***	Sputum Viral load
										***	*							Serum MN titer
**													**					SOFA Respiration
										*						**	*	SOFA SOFA Respiration Coagulation
										**				*	*	**	*	SOFA Liver
							*		***					*	***	**	***	SOFA Cardiovascular
*	*	***	**	**	***	***	**	***	**			**		***	***	*	*	SOFA Renal
*		*	*	**	**	***		**	**	***	*	***	**	***	***	**	***	SOFA Score
Eotaxin	G-CSF	MIP-1α	MIF	basic FGF	IL-1α	SCF	IL-12p40	IL-2Rα	HGF	IL-9	IL-1β	M-CSF	IL-1RA	IL-16	IFN-Y	IL-18	Mig	
 - -		0.5		S D D D						log,	₁₀ (p	g/m	L)					
 	י	SI	opeannan s mo	mon_	2.0-		2.5-		3.0-				ວ ກ	3.0-	3.5	I	4.0 -	4.5
				e rho			-	•-•]	,]					•		ן	1

┥╸┨╺

1

During BAX


After BAX

Before BAX

.

ns

*



IL-18


...

su

l

*

Mig




μ

Serum cytokines



2

Sputum cytokines



log₁₀(pg/mL) ______¥

σ

Ņ